Abstract. Increasing evidence suggests that interplays between Wnt/β-catenin and PI3K/AKT signaling cascades are involved in tumor development and progression. However, the exact mechanism in glioma is not well known. Using aspirin, we found that the expression levels of AKT1 in glioma cells significantly correlated with the transcriptional activity of β-catenin. Similar observations were made when we subjected glioma cells to treatment with Tcf4 siRNA. Moreover, both aspirin and Tcf4 siRNA can suppress the proliferation and induce apoptosis of glioma. In addition, our analysis of the gene promoter of AKT1 revealed multiple putative Tcf-4 binding sites. In support of the concept that β-catenin/Tcf-4 is a transcriptional regulator for AKT1, results from our chromatin immunoprecipitation studies and luciferase assay showed that β-catenin/Tcf-4 binds to the potential binding sites in the gene promoter of AKT1. Furthermore, using immunohistochemistry, we found that Tcf-4 protein expression increased significantly in high-grade glioma in comparison to low-grade glioma and correlated with AKT1 expression. In conclusion, our results support the concept that β-catenin/Tcf-4 directly regulates AKT1 in glioma, and these two proteins may cooperate with each other in exerting their oncogenic effects in glioma.
Introduction
β-catenin is known to function as an adhesion molecule that is associated with E-cadherin and actin filaments at the cell membrane (1) . In addition, it can act as a core factor involved in a number of cellular signaling pathways such as the Wnt canonical pathway and EGFR pathway (2) . Further, β-catenin plays a pivotal role in mammary development and tumorigenesis through its functions in cell adhesion, signal transduction and regulation of cell-context-specific gene expression (3) . As a cotranscripitonal factor, β-catenin was described to translocate into the nucleus. This nuclear translocation is regulated by several transcription factors of the TCF (T cell-factor) family such as Tcf-4 and Lef-1 (lymphoid-enhancer-factor-1), which were shown to interact with β-catenin (4, 5) . The β-catenin/TCF complex recruits further chromatin-remodeling proteins to responsive promoters, thereby activating the transcription of specific target genes, including c-myc, fra-1 and cyclin D1 (6) . Malignant gliomas are the most common primary brain tumors (7) . Although β-catenin has been reported to be abnormally expressed in a variety of human cancers, little is known in gliomagenesis.
AKT, a serine/threonine kinase, is the essential mediator in the PI3K/AKT pathway which regulates the survival and apoptosis balance by different machnism (8, 9) . Akt is also known to be involved in migration and invasion in cells of many different organisms (10) . The combination of activated Ras and Akt induces high-grade gliomas with the histological features of human GBMs (11) . Activated Akt1 prevents the phosphorylation and degradation of β-catenin by phosphorylating GSK-3β at ser9, which indicats the interplay between Wnt/β-catenin and AKT signaling (12) . Our previous data showed that downregulation of β-catenin by siRNA inhibites phosphorylation of AKT and suppresses malignant glioma cell growth (13) . However, the definite mechanism between β-catenin/Tcf-4 and AKT is not well explained. In this study, expression of the AKT1 was down-regulated both by aspirin and Tcf4 siRNA, leading us to the hypothesis that AKT1 might be regulated by β-catenin/Tcf-4. In addition, we established that transcription of AKT1 is indeed regulated by β-catenin/Tcf4 in glioma cells and overexpression of the AKT1 kinase co-localizes with high levels of Tcf4 in glioma samples. Western blot analysis. Prepared cells were lysed in 1% Nonidet P-40 lysis buffer after treatment. Homogenates were clarified by centrifugation at 20,000 x g for 15 min at 4˚C, and protein concentration was measured by the Lowry method. SDS-PAGE was performed on 40 µg of protein from each sample, gels were transferred to PVDF membranes (Millipore, USA) and incubated with primary antibodies against AKT1 (Cell Signaling Technology), Fra-1 (Santa Cruz Biotechnology), Tcf-4 (Santa Cruz Biotechnology), β-catenin (Cell Signaling Technology), and GAPDH, followed by incubation with HRP-conjugated secondary antibody (1:1000 dilution, Zymed, San Diego, CA). After washing with stripping buffer, the membrane was reprobed with antibody against GAPDH.
Patients and methods

Patients
Luciferase reporter assay. To evaluate the β-catenin/Tcf-4 transcriptional activity, we used a pair of luciferase reporter constructs, TOP-FLASH and FOP-FLASH (Upstate). TOP-FLASH (with three repeats of the Tcf-binding site) or FOP-FLASH (with three repeats of a mutated Tcf-binding site) plasmids were transfected into cells treated with aspirin, as instructed by the suppliers. Luciferase activity was measured with the Dual-luciferase reporter assay system, with the Renilla luciferase activity as an internal control, 48 h after transfection. In addition, pGL3-WT6-AKT1-promoter and pGL3-MUT6-AKT1-promoter reporters were were kindly provided by professor Susanne Dihlmann.
Subcutaneous tumor assay. LN229 glioma cells were subcutaneously injected to 5-week old female nude mice (Cancer Institute of The Chinese Academy of Medical Science). When the tumor volume reached 50 mm 3 , the mice were randomly divided into three groups (ten mice per group) which were treated with nonsense siRNA (50 nmol/lx10 µl) mixture, the control group (20 µl PBS) and Tcf-4 si group (a mixture of 20 µl Lipofectamine and Tcf-4 siRNA) local injection of xenograft tumor in multiple sites. The treatment was performed once every 2 days for 20 days. and the tumor volume was measured with a caliper every 2 days, using the formula volume = length x width 2 /2. At the end of 20-day observation period, the mice bearing xenograft tumors were sacrificed and the tumor tissues were removed for formalin fixation and preparation of paraffin embedded sections for immunohistochemical analysis.
Statistical analysis. Data were analyzed with SPSS 10.0. ANOVA, t-test, χ 2 test and Pearson's correlation were used to analyze the significance between groups. Statistical significance was assigned to P-values <0.05.
Results
Aspirin down-regulates β-catenin activity in glioma cells.
Previous work showed that transcription of Wnt/β-catenin target genes is inhibited by aspirin and indomethacin in CRC cells (14) . To determine whether this effect happens in gliomas, parallel samples of the LN229 and U87 cells were transiently transfected with a β-catenin/TCF-responsive luciferase reporter construct. In LN229 cells, aspirin reduced Topflash activity in a time-dependent manner at a concentration of 10 mM, 20% and 60% of Topflash activity was inhibited respectively in 6 and 24 h compared with untreated cells. U87 cells showed a similar result. Western blot showed the total amount of β-catenin and Tcf-4 were not decreased either in a time-or dose-dependent manner. Furthermore, one of the most important targets of β-catenin, Fra-1, showed reduced expression after the treatment by aspirin. Thus, aspirin down-regulates β-catenin activity in glioma cells in a time-and concentration-dependent manner (Fig. 1) .
Effect of β-catenin/Tcf-4 activity on glioma cell proliferation and apoptosis. To detect the biological effect of low β-catenin/ Tcf-4 transcriptional activity on glioma cell proliferation, MTT and Annexin V-PI assay were used. As shown in Fig. 2C , inhibition of β-catenin/Tcf-4 with asprin suppressed the proliferation of U87 and LN229 cells, beginning 24 h after administration and continuing throughout the 6-day observation period, as determined by MTT assay (Fig. 2A) . In contrast, acetone did not impact U87 and LN229 cell proliferation. As observed in the Annexin V-PI assay, the apoptosis percentage of control, acetone and aspirin group in LN229 cells was 3.16, 3.23 and 15.9%, respectively. Similar trend of apoptosis rate was detected in U87 cells. These results suggest that β-catenin/Tcf-4 activity is critical for glioma cell proliferation and apoptosis. 
Inhibition of Tcf-4 suppresses glioma xenograft growth and impacts on protein expression.
To explore the effect of β-catenin/ Tcf-4 activity on tumor growth in vivo, we employed a xenograft LN229 glioma mouse model treated with Tcf-4 siRNA. On day 8, the tumors of Tcf-4 si group started to reach statistical significance compared with control groups (P<0.05). At the termination of the study, the difference in tumor mass between Tcf4 group and control groups was marked (Fig. 6 ). After mice were observed for 20 days, the tumor samples were taken out, and paraffin-embedded section was prepared for immunohistopathological examination. In the course of analyzing the effect of Tcf-4 siRNA we observed that the protein level of Tcf-4 and AKT1 were similarly down-regulated as compared to those treated with scrambled siRNA.
The expression of AKT1 positively correlates with β-catenin/Tcf-4 activity. Next, we want to investigate whether the expression of AKT1 correlated with β-catenin/Tcf-4 in vitro. As anticipated, AKT1 was similarly down-regulated as well as β-catenin/Tcf-4 target gene Fra-1 treated by asprin. Moreover, using Tcf-4 siRNA, we identified a significant reduction of AKT1 expression and phosphorylation of AKT. SNB19 cells, which have low β-catenin and Tcf-4 expression, were transfected with Ad.β-catenin and/or Ad.Tcf-4 recombinant adenovirus. Overexpression of β-catenin and Tcf-4 in SNB19 cells induced an increase of AKT1 expression and phosphorylation of AKT. Therefore, we hypothesized that AKT1 expression might be a direct target of β-catenin/Tcf-4 complex in glioma cells (Fig. 3) . LN229 cells. Six primers were designed to amplify the putative β-catenin/Tcf-4-binding sites in our study. As shown in Fig. 4 , only primer 4 which targets binding site 6 showed amplifiable products. In contrast, no detectable amplification was observed for other primers. The input lanes were included as a control for the PCR effectiveness. PCR without the addition of DNA templates was used as a negative control.
To test the specificity of the TBE site 6 for transactivation by β-catenin/Tcf-4, TBE6 mutant and wild-type AKT1 promoter luciferase plasmids were transiently transfected into LN229 and U87 cells. Wild-type AKT1 promoter demonstrated a low activity after reduction of Tcf-4 and TBE6 mutant AKT1 promoter could abolish the inhibitory effect of Tcf-4 siRNA on luciferase activity. Thus, the putative TBE site 6 exhibits promoter activative function in glioma cells. Taken together, these results strongly support the hypothesis that β-catenin/Tcf-4 contribute to the regulation of AKT1 expression.
Tcf-4 and AKT1 expression positively correlate with glioma grades. Using immunohistochemistry, we surveyed the expression of Tcf4 and AKT1 in cohort of formalin-fixed, paraffin-embedded glioma samples. The results showed that Tcf-4 and AKT1 expression is positively correlated with glioma grades. Heat map representing gene expression level is shown in Fig. 5 . Pearson's correlation showed that a significant positive correlation existed between Tcf-4 and AKT1 expression (R=0.845, P<0.001) (Fig. 5B) . Accordingly, Tcf-4 expression increases significantly with the ascending pathologic grade of gliomas and correlates positively with AKT1 expression.
Reduction of AKT1 inhibits glioma cell proliferation and induces apoptosis.
To investigate the biological importance of AKT1 on glioma, we down-regulated AKT1 levels in LN229 and U87 using siRNA, and a significant down-regulation of AKT1 was shown on Western blotting (Fig. 6A) . The Annexin-PI analysis showed that apoptosisi was induced both in LN229 and U87 cells used by AKT1 si (Fig. 6B) . In addtion, MTT assay was also performed. As shown in Fig. 6C , there was a significant decrease in cell growth in cells treated with AKT1 siRNA, as compared to those treated with scrambled siRNA. The results suggest that glioma cell proliferation regulated by β-catenin/Tcf-4 activity is, in part, mediated by AKT1. 
Discussion
AKT, a serine/threonine kinase, also known as PKB, consists of three members: Akt1/PKBα, Akt2/PKBβ, and Akt3/PKBγ. All Akt family members share similar tructure with an N-terminal plekstrin homology domain and a C-terminal hydrophobic domain (15) . In order to be fully activated, Akt requires phosphorylation at two specific amino acid residues, threonine 308 and serine 473, respectively. Upon activation, Akt moves to the cytoplasm and nucleus where it phosphorylates downstream target proteins, including mTOR, FKHR, GSK-3, mdm2, IκB IKK, and BAD (16) , ultimately affecting a number of processes containing cell growth, survival, proliferation, metabolism, and motility and/or invasion. As we know, oncogenic activation of the PI3K signalling pathway plays a pivotal role in the development of GBM (17) . A central node in PI3K downstream signalling is controlled by the serine-threonine kinase AKT1. Previous data demonstrated that shRNA targeting Akt1 down-regulates its expression significantly in a sequence-specific manner, exerting proliferation and invasion inhibition effects on U251 cells (18) . In our study, immunohistochemistry assay showed that AKT1 expression is positively correlated with glioma grades. Reduction of AKT1 by siRNA significantly inhibits glioma cells proliferation and induces cell cycle arrest. Our results emphasize the importance of AKT1 in high grade glioma.
β-catenin and Tcf-4 are the core components of the canonical Wnt/β-catenin/Tcf pathway (5) . Upon translocation to the nucleus, β-catenin interacts with Tcf4 and Lef1, constituting a complex which binds to an evolutionarily conserved consensus motif on the promoter of target genes, including c-myc, cyclin D and Fra-1. In addition, plenty of new targets have recently been identified in the website of Stanford university (http://www. stanford.edu/~rnusse/pathways/targets.html). Multitude of target genes are known to play a pivotal role in controlling growth, proliferation of cells (19) (20) (21) . Recently, the Cancer Genome Atlas Network showed that the Proneural, one of the molecular subtype of glioblastoma, contains several signatures of proneural development genes, such as SOX and Tcf-4 (22) . Additionally, Proneural subtype of glioblastoma was considered of no benefit in the response to aggressive therapy. Our present study showed that reduction of Tcf-4 can decrease the expression of AKT1. Importantly, knockdown of Tcf-4 suppresses the proliferation of glioma both in vivo and in vitro. Accrodingly, these data suggest that Tcf-4 may play an important role in glioma progression and prognosis or prediction of response to therapy.
Our previous study demostrated that knockdown of β-catenin inhibited growth of glioma cells and down-regulated the expression of PI3K/AKT pathway, indicating the interplay between Wnt/β-catenin and AKT signaling cascades. Moreover, Liu et al, recently reported that Wnt/β-catenin pathway corre- lated closely with the progression of gliomas and might be a novel prognostic marker for this neoplasm. In literature, most of dowmstream genes were directly regulated by β-catenin/Tcf were reported in colorect cancer (23) (24) (25) . Few studies reported the transcript regulation of β-catenin/Tcf in glioma. Here, we establish that down-regulation of β-catenin/Tcf activity induces glioma cell apoptosis, and suppresses the proliferation of glioma. These effects are mediated in part by the direct transcriptional regulation of the oncogenic AKT1. We demonstrate that Tcf-4 directly targets the promoter regions of AKT1 and induces the transcription of AKT1 by CHIP assay and luciferase assay respectively. Furthermore, knockdown of AKT1 results in a similar effect compared to treatment with Tcf-4 siRNA.
In conclusion, our present studies establish that β-catenin/ Tcf-4 activity regulates AKT1 expression by binding to the AKT1 promoter, thereby modulating glioma cell growth. In addition, we indicate that Tcf-4 expression increases significantly with the ascending pathologic grade of gliomas and correlates positively with AKT1 expression. Since specific agents inhibiting β-catenin/Tcf-4 and AKT1 are available (26, 27) , our data provide the rationale for combining these inhibitors in treating specific forms of cancer, such as in a subset of glioma in which both β-catenin/Tcf-4 and AKT1 are activated.
